Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Shin Fujisawa1 · Yasunori Ueda2 · Kensuke Usuki3 · Hajime Kobayashi4 · Eisei Kondo5 · Noriko Doki6 · Takafumi Nakao7 · Yoshinobu Kanda8 · Nobuharu Kosugi9 · Hiroshi Kosugi10 · Takashi Kumagai11 · Hiroshi Harada12 · Masato Shikami13 · Yasuhiro Maeda14 · Toru Sakura15 · Koiti Inokuchi16 · Akio Saito17 · Yuichiro Nawa18 · Masahiro Ogasawara19 · Junji Nishida20 · Takeshi Kondo21 · Chikashi Yoshida22 · Hiroyuki Kuroda23 · Yoko Tabe24 · Yoshinobu Maeda25 · Kenji Imajo26 · Kensuke Kojima27 · Satoshi Morita28 · Sho Komukai29 · Atsushi Kawaguchi30 · Junichi Sakamoto31 · Shinya Kimura27

Received: 4 September 2018 / Accepted: 5 November 2018 / Published online: 12 November 2018 © The Author(s) 2018

Abstract
Background Treatment-free remission (TFR), the ability to maintain a molecular response (MR), occurs in approximately 50% of patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs).

Methods A multicenter phase 2 trial (Delightedly Overcome CML Expert Stop TKI Trial: DOMEST Trial) was conducted to test the safety and efficacy of discontinuing imatinib. Patients with CML with a sustained MR of 4.0 or MR4.0-equivalent for at least 2 years and confirmed MR4.0 at the beginning of the study were enrolled. In the TFR phase, the international scale (IS) was regularly monitored by IS-PCR testing. Molecular recurrence was defined as the loss of MR4.0. Recurrent patients were immediately treated with dasatinib or other TKIs including imatinib.

Results Of 110 enrolled patients, 99 were evaluable. The median time from diagnosis to discontinuation of imatinib was 103 months, and the median duration of imatinib therapy was 100 months. Molecular recurrence-free survival rates were 69.6%, 68.6% and 64.3% at 6, 12, and 24 months, respectively. After discontinuation of imatinib therapy, 26 patients showed molecular recurrence, and 25 re-achieved deep MR after dasatinib treatment. Molecular response MR4.0 was achieved in 23 patients within 6 months and 25 patients within 12 months. Multivariate analysis revealed that a longer time from diagnosis to discontinuation of imatinib therapy (p = 0.0002) and long duration of imatinib therapy (p = 0.0029) predicted a favorable prognosis.

Conclusions This DOMEST Trial showed the feasibility of TKI discontinuation in a Japanese clinical setting.

Keywords Chronic myelogenous leukemia · Treatment-free remission · Imatinib · Deep molecular response · Molecular recurrence-free survival

Introduction
Chronic myelogenous leukemia (CML) is a disease in which granulocytes proliferate irreversibly. The major etiology is the Philadelphia (Ph) chromosomal abnormality, which gives rise to the BCR–ABL fusion gene that is translated into the BCR–ABL fusion protein. CML is a hematopoietic malignancy that progresses from the chronic phase (CP) to the accelerated phase (AP), followed by the blast phase (BP).
patients with CML remains a problem. In the Stop Imatinib (STIM) study reported in 2010, approximately 40% of CML patients who achieved deep molecular response (DMR) for more than 2 years were able to safely stop imatinib [3, 4]. Several studies reported that approximately one-half of patients with CML around the world, including Japan, who maintain a molecular response (MR) to TKIs can achieve treatment-free remission (TFR) [5–9]. Furthermore, the stop second-generation (2G)-TKI multicenter observational study investigated the discontinuation of 2G-TKIs (dasatinib or nilotinib) in CML and found an earlier response than that to imatinib [10, 11].

In Japan, real-time quantitative polymerase chain reaction (RQ-PCR) analysis of BCR–ABL was not covered by the National Insurance until April 2015. As a result, TFR after imatinib treatment has not been investigated in detail in Japan. Here, we conducted a multicenter phase 2 trial (Delightedly Overcome CML Expert Stop TKI trial: DOMEST Trial) to test the safety and efficacy of discontinuing imatinib after at least 2 years of MR4.0-equivalent sustained MR (UMIN Clinical Trials Registry UMIN000012472).

Patients and methods

Study design and patients

The DOMEST Trial is a phase 2, multicenter, single-arm study performed in Japan. Patients were enrolled if they had CML-CP with a sustained MR of 4.0 or MR4.0-equivalent [negative results of nested reverse transcriptase PCR (RT-PCR) assay or a highly sensitive transcription-mediated amplification method assay] for at least 2 years and confirmed MR4.0 by RQ-PCR at the beginning of the study. In the TFR phase after stopping imatinib, BCR–ABL international scale (IS)% was regularly monitored by IS-PCR testing every month for the first year and every 3 months during the second year. When molecular recurrence was detected, patients were immediately treated with dasatinib or other TKIs (including imatinib, if the patients wished). The rate of molecular recurrence was assessed in patients with at least 12 months of follow-up.

The present survey was conducted in accordance with the Declaration of Helsinki. Approval of the study protocols was obtained from the appropriate review committee or ethical committee of each institute. Written informed consent was obtained from each patient.

Endpoints

The primary endpoint was the molecular recurrence-free survival (MRFS) rate at 6 months after discontinuation of imatinib. The secondary endpoints were the MRFS rate at 12 and 24 months after discontinuation of imatinib. Previous interferon therapy, sex, Sokal risk group, and total duration of imatinib treatment were assessed as potential prognostic factors for MRFS. The DMR rate and time to DMR of PCR-positive patients based on PCR screening during dasatinib treatment after molecular recurrence were evaluated.

Definitions

RQ-PCR analysis was performed by Bio Medical Laboratories (BML) Inc. (Tokyo, Japan). DMR was defined as the peripheral Major (M)-BCR–ABL/ABL transcript ratio below the detection limit of the RQ-PCR analysis widely used throughout Japan [12]. Major MR (MMR) was defined as 3-log reduction (BCR–ABL<0.1%), and MR4.0 was defined as 4-log reduction in BCR–ABL transcripts (\(BCR–ABL<0.01\)). Molecular recurrence was defined as loss of MR4.0 in two consecutive analyses or one loss of MR3.0 and BCR–ABL mRNA detected in two consecutive occurrences by RQ-PCR (peripheral blood) after discontinuation of imatinib treatment. Loss of MMR was defined as recurrence at that point in one measurement. MRFS was defined as the period from registration to molecular recurrence or death. Patients who died without confirmation of molecular recurrence were assumed to have progressed on the day of death. DMR with molecular recurrence after discontinuation of imatinib treatment was evaluated by BCR–ABL mRNA RQ-PCR for 18 months (1, 3, 6, 9, 12, 15, and 18 months after initiation of dasatinib). If the results were consecutively negative, the first PCR-negative day was considered the second DMR achievement date.

Statistical analysis

The primary endpoint was estimated as the percentage of the 95% confidence interval (CI) for MRFS at 6 months after discontinuation of imatinib. The analysis determined whether the lower limit of the CI exceeded the threshold and whether the main objective of the study was achieved. The inclusion of 89 patients was required to achieve 90% power to reject the null hypothesis with a one-sided \(\alpha\)-error of 5% if the 6-month MRFS rate was \(\geq 45\)%, as established by Mahon et al. [3].

The number of registered cases was set at 100 patients. Previous interferon therapy, sex, Sokal risk group, and total duration of imatinib treatment were evaluated as potential prognostic factors for MRFS. The DMR rate of patients retreated with dasatinib was evaluated in patients with molecular recurrence after discontinuation of imatinib. The groups were compared using the Kaplan–Meier method and log-rank test. Univariate and multivariate Cox regression analyses were performed to
identify covariates predicting longer MRFS. A stepwise multivariate approach was used to identify the most important prognostic factors with variable retention criteria for two-sided \( p < 0.05 \). For the multivariate model, variables showing significant relationships were used. Statistical analysis and graphical user interface were performed using statistical computing R. The cutoff data for the inclusion of data were 10/10/2017.

## Results

### Patient characteristics

Patients were treated in 25 participating institutions between January 2014 and May 2015 (Fig. 1). Eleven patients were excluded (two patients were ineligible, three withdrew informed consent before main registration, one dropped out because of a different choice of treatment, and five had missing data). Of the 110 enrolled patients, 99 (65 men and 34 women with a median age of 62 years) were evaluable (Table 1). Nine patients (9%) were classified into the high-risk group according to the Sokal risk score. Sixteen patients (16%) were treated with interferon-α (IFN-α) before imatinib therapy. The median duration of IFN-α therapy was 22 (range 1–61) months, and one case was unknown. The median time from diagnosis to discontinuation of imatinib was 103 (range 29–287) months. The median duration of imatinib therapy was 100 (range 28–160) months and the MR4.0 or MR4.0-equivalent period was 55 (range 24–133) months. The median duration of DMR was 55 (range 24–133) months.

### Table 1 Patient characteristics

| Evaluable patients | n = 99 |
|--------------------|-------|
| **Age (years)**    |       |
| Median (range)     | 62 years (27–88) |
| 62                 | 50 |
| > 62               | 49 |
| **Sex**            |       |
| Male               | 65 |
| Female             | 34 |
| **Sokal score**    |       |
| Low                | 56 |
| Intermediate       | 34 |
| High               | 9 |
| **Previous therapy (IFN-α)** |       |
| Yes                | 16 |
| No                 | 83 |
| **Time from diagnosis to discontinuation of imatinib (months)** |       |
| Median (range)     | 103 (29–287) |
| 103                | 51 |
| > 103              | 48 |
| **Imatinib therapy duration (months)** |       |
| Median (range)     | 100 (28–160) |
| 100                | 51 |
| > 100              | 48 |
| **Duration of DMR (months)** |       |
| Median (range)     | 55 (24–133) |
| 55                 | 50 |
| > 55               | 49 |

*IFN-α interferon-α, DMR deep molecular response*
MRFS rates at 6, 12, and 24 months

The MRFS rates were 69.6% (95% CI 59.5–77.7%), 68.6% (95% CI 58.4–76.7%), and 64.3% (95% CI 54.0–72.9%) at 6, 12, and 24 months, respectively (Fig. 2).

Induction of TKIs after molecular recurrence

After discontinuation of imatinib therapy, 35 patients showed molecular recurrence, of which 26 were retreated with dasatinib and nine with imatinib. Of the 26 patients retreated with dasatinib, 21 (80.8%) re-achieved DMR within 6 months and 25 (96.2%) within 12 months. The cumulative rate of MR4.0 re-achieved after dasatinib treatment was 96.2% (95% CI 83.6–99.7%). One patient did not re-achieve MR4.0 by 18 months, but achieved MMR (Fig. 3).

Fig. 2  Kaplan–Meier curve of molecular recurrence-free survival (MRFS). MRFS rate at 12 months: 0.686 (95% CI 0.584–0.767)

Fig. 3  Cumulative incidence of MR4.0 re-achieved after dasatinib treatment. Twenty-one patients within 6 months and 25 within 12 months re-achieved DMR with dasatinib treatment
Factors associated with MRFS

The results of the univariate analysis of factors affecting molecular recurrence in 99 patients are shown in Table 2. The MRFS rate was significantly higher in patients with a time from diagnosis to discontinuation of imatinib > 103 months than in those with a shorter duration of treatment ($p = 0.0487$, Fig. 4-a). The MRFS rates were significantly higher in low- and intermediate-risk patients according to the Sokal score than in high-risk patients, as determined by univariate analysis ($p = 0.0787$, Fig. 4-b).

Multivariate analysis revealed that a longer time from diagnosis to the discontinuation of imatinib and long duration of imatinib were predictive of better prognosis, whereas a high-risk classification according to the Sokal score was predictive of worse prognosis (Table 3).

Discussion

The introduction of imatinib dramatically improved the prognosis of patients with CML. In Japan, three ABL TKIs including imatinib, dasatinib and nilotinib are approved for the first-line treatment of CML. Second-generation ABL TKIs including dasatinib and nilotinib induced more rapid and deeper molecular response compared with imatinib according to DASSION and ENESTnd study [13, 14]. Based on these studies, the second-generation ABL TKIs currently tend to be chosen mainly as for the first-line treatment in Japan. However, it is also true that there is no significant difference on overall survival (OS) in patients treated either with imatinib, dasatinib or nilotinib. In point of adverse effects, it may be possible to select optimal ABL TKI for each patient. There are characteristic adverse events such as pleural effusion in dasatinib, hyperglycemia in nilotinib, and commonly cardiovascular disorders. Therefore, imatinib might be safer in patients with chest disorders, diabetes and cardiovascular events as past histories.

Stopping TKI treatment is difficult because CML stem cells cannot be eradicated, and the lifelong administration of TKIs is a problem. The possibility of TFR after discontinuation of imatinib was first evaluated in the STIM study in 100 patients with complete MR for at least 2 years [3, 4]. At the median follow-up of 65 months, the relapse-free survival was 39% at 24 months after discontinuation of imatinib. Similar findings were reported in subsequent TKI discontinuation trials [15]. Furthermore, most cases retreated with TKIs after recurrence re-achieve DMR. Therefore, patients with CML who meet the qualifying requirements and are

| Table 2 Univariate analysis for molecular recurrence-free survival | MRFS (95% CI) | $p$ value |
| --- | --- | --- |
| Age | | |
| > 62 | 0.714 (0.565–0.819) | 0.714 (0.565–0.819) |
| ≤ 62 | 0.68 (0.532–0.79) | 0.66 (0.511–0.773) |
| Sex | | |
| Male | 0.737 (0.612–0.828) | 0.737 (0.612–0.828) |
| Female | 0.618 (0.434–0.757) | 0.588 (0.406–0.732) |
| Sokal score | | |
| Low | 0.713 (0.574–0.813) | 0.694 (0.555–0.798) |
| Intermediate | 0.735 (0.553–0.853) | 0.735 (0.553–0.853) |
| High | 0.444 (0.136–0.719) | 0.444 (0.136–0.719) |
| Previous therapy (IFNα) | | |
| Yes | 0.75 (0.463–0.898) | 0.75 (0.463–0.898) |
| No | 0.685 (0.573–0.774) | 0.673 (0.561–0.763) |
| Time from diagnosis to the discontinuation of imatinib | | |
| > 103 | 0.771 (0.625–0.866) | 0.771 (0.625–0.866) |
| ≤ 103 | 0.625 (0.477–0.742) | 0.605 (0.456–0.724) |
| Imatinib therapy duration | | |
| > 100 | 0.729 (0.58–0.833) | 0.729 (0.58–0.833) |
| ≤ 100 | 0.664 (0.516–0.776) | 0.644 (0.496–0.759) |
| Duration of DMR | | |
| > 55 | 0.714 (0.566–0.82) | 0.694 (0.544–0.803) |
| ≤ 55 | 0.678 (0.529–0.789) | 0.678 (0.529–0.789) |

MRFS molecular recurrence-free survival
trying to discontinue TKI treatment are considered safe [15–17].

Achieving TFR not only reduces the burden of expensive drug costs for patients, but also has a positive impact on the medical economy. In the DOMEST study, the MRFS was 69.6%, 68.6% and 64.3% at 6, 12, and 24 months, respectively (Fig. 2). However, molecular recurrence was defined as loss of MMR in the JALSG-STIM 213 study, and the results of the DOMEST study were similar to those of the JALSG-STIM 213 study [5]. In the JALSG-STIM 213 study, the median age was 55 years; 16.2% were Sokal high-risk patients (Fig. 3).

Table 3 Multivariate analysis with the stepwise method for molecular recurrence-free survival

|                         | HR (95% CI) | p value |
|-------------------------|-------------|---------|
| Time from diagnosis to  |             |         |
| the discontinuation     | 0.05 (0.01–0.25) | 0.0002  |
| of imatinib             |             |         |
| Imatinib therapy        | 9.14 (2.14–39.08) | 0.0029  |
| duration                |             |         |
| Sokal risk              | 3.38 (1.27–8.99) | 0.0144  |

HR hazard ratio

Fig. 4 Kaplan–Meier curve of MRFS according to the time from diagnosis to the discontinuation of imatinib and Sokal score. a Kaplan–Meier curve of MRFS according to the time from diagnosis to the discontinuation of imatinib. MRFS rates were significantly higher in patients in which the time from diagnosis to the discontinuation of imatinib was > 103 months than in those with a shorter duration of treatment by univariate analysis (p = 0.0487). b Kaplan–Meier curve of MRFS according to Sokal score, MRFS rates were significantly higher in patients with Sokal score low or intermediate risk than in high-risk patients by univariate analysis (p = 0.0374).

Table 3 Multivariate analysis with the stepwise method for molecular recurrence-free survival.
patients, and 19.1% were treated with IFN-α before imatinib therapy. The median duration of imatinib treatment was 97.5 (range 78–130) months, and the 12-month TFR rate was 67.6%. In the present DOMEST study, the median age was slightly higher at 62 years, 9% were classified as high risk, and 16.2% were treated with IFN-α. The median duration of imatinib treatment was 100 (range 28–160) months (Table 1). Despite a slight background difference between the JALSG-STEM 213 study and the present DOMEST study, the results of the Japanese TKI discontinuation study indicate that a high TFR rate is achievable.

In previous trials, the resumption of TKI therapy immediately after recurrence resulted in the achievement of DMR in almost all patients [15]. Approximately 25–42% of patients who discontinue imatinib may experience imatinib withdrawal syndrome [3, 10, 18]. In the DOMEST study, withdrawal syndrome data were not collected, and this needs to be investigated in the future.

Studies have identified several factors for predicting recurrence after discontinuation of TKI therapy, including Sokal risk score, sex, natural killer (NK) counts, T-cell counts, suboptimal response, resistance to imatinib, duration of TKI therapy, and duration of DMR prior to TKI discontinuation [15, 19]. In the present DOMEST study, a long time period from diagnosis to the discontinuation of imatinib and long duration of imatinib therapy were predictive of better prognosis, whereas a Sokal high-risk classification was a poor predictive factor for MRFS, consistent with previous reports [3, 10]. Takahashi et al. conducted a meta-analysis of the association between the median duration of TKI and the TFR rate [5]. The duration of TKI treatment was identified as a predictive factor for TFR in previous studies [3, 4, 7, 20], and some studies reported that deeper MRs predict a greater success of TFR [8, 18]. The recent EURO-Ski study showed that the duration of DMR is more important when adjusting for the duration of TKI treatment [9]. This result may reflect early MR (EMR), because it predicts a longer duration of DMR for any given duration of TKI administration. The rates of MR and EMR are indicators of TKI sensitivity, and these were previously identified as good predictors of TFR [6, 21]. In the DOMEST study, there was no significant association between DMR duration and MRFS.

Before the introduction of TKIs, an increase of NK cells is reported in patients who discontinue IFN-α [22]. A high number of circulating NK cells and other immunological parameters are significantly correlated with improved rates of TFR [19]. In the DOMEST study, the presence of functional NK cells at the time of discontinuation of imatinib was not assessed. Dasatinib causes an increase in large granular lymphocytes (LGLs), and its therapeutic effect is high in cases with increased LGLs [23, 24]. On the basis of these results, NK cell immunity is currently considered important for the TFR of patients with CML.

The goal of CML therapy is to achieve EMR, discontinue TKIs, and maintain TFR. The cumulative 5 year MR4.5 rate in the ILIS, ENESTnd, and DASISION studies was 40.2%, 42% and 54%, respectively [13, 14, 25]. In the present DOMEST study, the 12-month TFR was 68.6%. However, if TFR is achieved by 60% of patients in the ILIS, ENESTnd, and DASISION studies, only 24.1%, 25.2%, and 32.4% of the initial CML patients can maintain TFR, respectively. To further improve the TFR rate, it is necessary to improve the DMR or the definition of recurrence, the methods of TKI discontinuation, and other variables. The results of ISAV study using digital PCR method to detect fewer minimal residual disease (MRD) in imatinib-treated CML patients showed the usefulness of the digital PCR [8]. However, the difference on the MRD levels between imatinib and second-generation ABL TKIs was not examined. In addition, it is still controversial whether deeper molecular genetic remission really increases TFR rate or not.

According to the Japanese Society of Hematology guidelines, CML patients should only discontinue imatinib therapy in the context of clinical studies [26]. However, several guidelines are presented as criteria for TKI discontinuation outside clinical trials [15–17]. Further, several patients cannot discontinue TKI therapy because there are few TKI discontinuation studies, despite the existence of patients who wish to discontinue therapy. Imatinib discontinuation could be most acceptable at present to observe the ESLO guidelines such as treatment by imatinib for more than 5 years including more than 2-year DMR [17].

The evidence from the JALSG-STEM 213 study and the present DOMEST study suggests that TKI discontinuation outside the clinical trial setting can be achieved by adapting existing guidelines.

In conclusion, the present phase 2 DOMEST study provided insight into the feasibility of stopping TKI treatment in the Japanese clinical setting, and the outcome was comparable with that of other studies investigating TFR.

Acknowledgements This study was supported by the Epidemiological and Clinical Research Information Network (ECRIN). We thank Yumi Miyashita at ECRIN for collecting the data and Yoshinori Yamamoto at BML for measuring the data.

Compliance with ethical standards

Conflict of interest S. Fujisawa has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding form Pfizer and Novartis. K. Usuki has received honoraria from MSD K.K, Sumitomo Dainippon Pharma, Pfizer Japan, Celgene Corporation, Novartis, Ono Pharmaceutical, Takeda Pharmaceuticals, Chugai Pharmaceutical, Nippon Shinyaku, and Mochida Pharmaceutical and research funding from MSD K.K, Sumitomo Dainippon Pharma, Pfizer Japan, Celgene Corporation, Astellas Pharma, Otsuka, Kyowa Kirin, Glaxo Smithkline K.K, Sanofi K.K, Shire Japan, Symbio Pharmaceuticals Limited, Daiichi Sankyo, Boehringer-Ingelheim Japan, and Janssen Pharmaceutical K.K. Y.
Kanda has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding from Pfizer and Otsuka Pharmaceuticals. T. Kumagai has held an advisory role for Novartis and Otsuka Pharmaceutical and has received honoraria from Bristol-Myers Squibb, Celgene, Novartis, and Pfizer and research funding from Bristol-Myers Squibb. T. Kondo has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Celgene and research funding from Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceuticals. K. Kojima has held an advisory role for Janssen Asia Pacific (Singapore) and has received research funding from Janssen Global (USA), and PTC Therapeutics (USA). S. Morita has received honoraria from Bristol-Myers Squibb, and Pfizer. J. Sakamoto has held an advisory role for Takeda and has received honoraria from Chuigai, Nihon Kayaku, and Tsumura. S. Kimura has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Ohara pharmaceutical. All remaining authors declare no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Bower H, Bjorkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851–2857
2. Hamilton A, Helgason GV, Schmionek M et al (2012) Chronic myeloid leukemia stem cells are not dependent on BCR-ABL kinase activity for their survival. Blood 119:1501–1510
3. Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029–1035
4. Etienne G, Guilhot J, Rea D et al (2017) Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298–305
5. Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment–free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG–STIM213 study. Int J Hematol 106:105–1059
6. Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522
7. Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424–430
8. Mori S, Vagge E, Le Coutre P et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90:910–914
9. Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747–757
10. Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528–e535
11. Mahon FX, Boquimpani C, Kim DW et al (2018) Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase. Results from a single-group, phase 2, open-label study. Ann Intern Med 168:461–470
12. Yoshida C, Fletcher L, Ohashi K et al (2012) Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 17:584–589
13. Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34:2333–2340
14. Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044–1054
15. Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:17–23
16. NCCN Clinical practice guidelines in oncology. Chronic Myeloid Leukemia Version 4. 2018-January 24, 2018
17. Hochhaus A, Saussele S, Rosti G et al (2017) Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv41–i51
18. Lee SE, Choi SY, Song HY et al (2016) Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101:717–723
19. Ilander M, Olsson-Stromberg U, Schlums H et al (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108–1116
20. Saussele S, Richter J, Hochhaus A et al (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638–1647
21. Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818–3824
22. Kreutzman A, Rohon P, Faber E et al (2011) Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 6:e23022
23. Kim DH, Kamel-Reid S, Chang H et al (2009) Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135–139
24. Mustjoki S, Ekblom M, Arstila TP et al (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398–1405
25. Hochhaus A, Larson RA, Guilhot F et al (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376:917–927
26. Shimoda K, Kawaguchi T, Kizaki M (eds) (2018) CML/MPN 2018 JSH Practical guidelines for hematological malignancies. Tokyo: Kanehara Shuppan, Co. Ltd.
Affiliations

Shin Fujisawa1 · Yasunori Ueda2 · Kensuke Usuki3 · Hajime Kobayashi4 · Eisei Kondo5 · Noriko Doki6 · Takaomi Nakao7 · Yoshinobu Kanda8 · Nobuharu Kosugi9 · Hiroshi Kosugi10 · Takashi Kumagai11 · Hiroshi Harada12 · Masato Shikami13 · Yasuhiro Maeda14 · Toru Sakura15 · Koiti Inokuchi16 · Akio Saito17 · Yuichiro Nawa18 · Masahiro Ogasawara19 · Junji Nishida20 · Takeshi Kondo21 · Chikashi Yoshida22 · Hiroyuki Kuroda23 · Yoko Tabe24 · Yoshinobu Maeda25 · Kenji Imajo26 · Kensuke Kojima27 · Satoshi Morita28 · Sho Komukai29 · Atsushi Kawaguchi30 · Junichi Sakamoto31 · Shinya Kimura27

1 Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
2 Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan
3 Department of Hematology, NTT Medical Center, Tokyo, Japan
4 Department of Hematology, Obihiro Kosei Hospital, Obihiro, Japan
5 Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
6 Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
7 Department of Hematology, Osaka City General Hospital, Osaka, Japan
8 Department of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
9 Department of Hematology, Numazu City Hospital, Numazu, Japan
10 Department of Hematology, Ogaki Municipal Hospital, Ogaki, Japan
11 Department of Hematology, Ome Municipal General Hospital, Ome, Japan
12 Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
13 Department of Hematology, Daiyukai General Hospital, Ichinomiya, Japan
14 Department of Hematology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan
15 Department of Hematology, Saiseikai Maebashi Hospital, Maebashi, Japan
16 Department of Hematology, Nippon Medical School, Tokyo, Japan
17 Department of Hematology, Fujioka General Hospital, Fujioka, Japan
18 Department of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan
19 Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
20 Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
21 Department of Hematology, Hokkaido University Hospital, Sapporo, Japan
22 Department of Hematology, National Hospital Organization Mito Medical Center, Mito, Japan
23 Department of Gastroenterology and Hematology/Clinical Oncology, Steel Muroran Memorial Hospital, Muroran, Japan
24 Department of Next Generation Hematology Laboratory Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
25 Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan
26 Department of Internal Medicine, Okayama Municipal Hospital, Okayama, Japan
27 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
28 Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
29 Division of Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
30 Division of Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
31 Tokai Central Hospital, Kakamigahara, Japan